OneSource Specialty Pharma Limited (BOM:544292)
India
· Delayed Price · Currency is INR 1,671.50
+23.00 (1.40%)
At close: Dec 4, 2025
BOM:544292 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 |
| Revenue | 15,215 | 14,449 | 1,719 | 387.14 |
| Revenue Growth (YoY) | - | 740.43% | 344.07% | - |
| Cost of Revenue | 4,804 | 4,966 | 852.13 | 336.43 |
| Gross Profit | 10,412 | 9,483 | 867.06 | 50.71 |
| Selling, General & Admin | 2,469 | 2,324 | 825.5 | 749.29 |
| Other Operating Expenses | 2,770 | 2,514 | 844.61 | 808.7 |
| Operating Expenses | 7,987 | 7,577 | 2,433 | 2,215 |
| Operating Income | 2,424 | 1,906 | -1,566 | -2,164 |
| Interest Expense | -1,285 | -1,541 | -853.99 | -401.06 |
| Interest & Investment Income | 149.44 | 149.44 | 17.65 | 14.67 |
| Currency Exchange Gain (Loss) | 27.19 | 27.19 | -5.75 | -91.59 |
| Other Non Operating Income (Expenses) | -107.73 | -112.1 | -38.97 | -73.21 |
| EBT Excluding Unusual Items | 1,208 | 428.87 | -2,447 | -2,715 |
| Gain (Loss) on Sale of Investments | 11.17 | 11.17 | 7.57 | 1.15 |
| Gain (Loss) on Sale of Assets | -2.25 | -2.25 | -58.08 | - |
| Asset Writedown | -1,108 | -1,108 | -1,159 | -1,451 |
| Pretax Income | 183.42 | -670.66 | -3,657 | -4,156 |
| Income Tax Expense | -223 | -497.85 | - | - |
| Earnings From Continuing Operations | 406.42 | -172.81 | -3,657 | -4,156 |
| Earnings From Discontinued Operations | -6.9 | -6.9 | -254.68 | -3,842 |
| Net Income | 399.52 | -179.71 | -3,912 | -7,998 |
| Net Income to Common | 399.52 | -179.71 | -3,912 | -7,998 |
| Shares Outstanding (Basic) | 113 | 110 | 42 | 40 |
| Shares Outstanding (Diluted) | 113 | 110 | 42 | 40 |
| Shares Change (YoY) | - | 165.73% | 4.34% | - |
| EPS (Basic) | 3.52 | -1.63 | -94.15 | -200.87 |
| EPS (Diluted) | 3.52 | -1.63 | -94.15 | -200.87 |
| Free Cash Flow | -3,929 | -1,960 | -1,710 | -2,068 |
| Free Cash Flow Per Share | -34.62 | -17.75 | -41.15 | -51.93 |
| Gross Margin | 68.43% | 65.63% | 50.43% | 13.10% |
| Operating Margin | 15.93% | 13.19% | -91.09% | -558.99% |
| Profit Margin | 2.63% | -1.24% | -227.53% | -2066.00% |
| Free Cash Flow Margin | -25.82% | -13.57% | -99.45% | -534.07% |
| EBITDA | 4,896 | 4,367 | -665.97 | -1,507 |
| EBITDA Margin | 32.18% | 30.23% | -38.74% | - |
| D&A For EBITDA | 2,472 | 2,462 | 900.01 | 656.8 |
| EBIT | 2,424 | 1,906 | -1,566 | -2,164 |
| EBIT Margin | 15.93% | 13.19% | -91.09% | - |
| Revenue as Reported | 15,395 | 14,623 | 1,761 | 414.06 |
| Advertising Expenses | - | 18.2 | 5.04 | 10.44 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.